DAAN Biotherapeutics Signs Antibody Exclusive Licensing Agreement with LigaChem Biosciences for ADC (Antibody-Drug Conjugate) Therapeutic Development ...Middle East

SEOUL, South Korea, Feb. 13, 2025 /PRNewswire/ -- DAAN Biotherapeutics, a leading innovative drug development company specializing in T-cell receptor (TCR)- based therapies, has signed an exclusive licensing agreement with LigaChem Biosciences for a novel tumor-targeting antibody to...

Read More Details
Finally We wish PressBee provided you with enough information of ( DAAN Biotherapeutics Signs Antibody Exclusive Licensing Agreement with LigaChem Biosciences for ADC (Antibody-Drug Conjugate) Therapeutic Development )

Also on site :

• Brynn Whitfield Announces Exit From 'RHONY' After Two Seasons
• Pop Princess Covers Classic ‘70s Rock Hit: ‘This Is So Good’
• Born on One of These 4 Dates? You're a Wise, Old Soul